Hyperion DeFi, Inc. (NASDAQ:HYPD) Given Consensus Recommendation of “Hold” by Analysts

Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) have been assigned a consensus rating of “Hold” from the five research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $4.5833.

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Thursday, January 22nd. Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi in a research note on Tuesday, December 16th. They set an “overweight” rating and a $4.00 target price for the company. Chardan Capital set a $7.75 price target on shares of Hyperion DeFi and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Zacks Research upgraded Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th.

Hyperion DeFi Trading Down 3.8%

Hyperion DeFi stock opened at $3.52 on Friday. Hyperion DeFi has a 52 week low of $0.85 and a 52 week high of $17.18. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The firm has a market capitalization of $28.76 million, a price-to-earnings ratio of -0.87 and a beta of 2.69. The company has a 50 day moving average price of $3.59 and a 200 day moving average price of $6.46.

Hyperion DeFi (NASDAQ:HYPD) last issued its quarterly earnings results on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $0.36 million for the quarter. Research analysts forecast that Hyperion DeFi will post -41.6 EPS for the current year.

Insider Transactions at Hyperion DeFi

In other news, Director Ellen R. Strahlman acquired 11,856 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were purchased at an average price of $3.61 per share, for a total transaction of $42,800.16. Following the completion of the acquisition, the director owned 34,869 shares of the company’s stock, valued at approximately $125,877.09. This represents a 51.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael S. Geltzeiler acquired 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were acquired at an average cost of $3.01 per share, for a total transaction of $90,300.00. Following the transaction, the director owned 88,015 shares of the company’s stock, valued at approximately $264,925.15. This represents a 51.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 189,204 shares of company stock valued at $611,467 in the last quarter. Corporate insiders own 10.86% of the company’s stock.

Hedge Funds Weigh In On Hyperion DeFi

Several hedge funds have recently bought and sold shares of HYPD. Sanctuary Advisors LLC bought a new stake in shares of Hyperion DeFi during the 4th quarter worth about $38,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Hyperion DeFi in the fourth quarter valued at approximately $40,000. Finally, Formidable Asset Management LLC acquired a new stake in shares of Hyperion DeFi in the fourth quarter worth $83,000. 25.84% of the stock is owned by institutional investors and hedge funds.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.